Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Leypoldt, Lisa B.; Tichy, Diana; Besemer, Britta; Haenel, Mathias; Raab, Marc S.; Mann, Christoph; Munder, Markus; Reinhardt, Hans Christian; Nogai, Axel; Goerner, Martin; Ko, Yon-Dschun; de Wit, Maike; Salwender, Hans; Scheid, Christof; Graeven, Ullrich; Peceny, Rudolf; Staib, Peter; Dieing, Annette; Einsele, Hermann; Jauch, Anna; Hundemer, Michael; Zago, Manola; Pozek, Ema; Benner, Axel; Bokemeyer, Carsten; Goldschmidt, Hartmut; Weisel, Katja C.

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Author:

Leypoldt, Lisa B.; Tichy, Diana; Besemer, Britta; Haenel, Mathias; Raab, Marc S.; Mann, Christoph; Munder, Markus; Reinhardt, Hans Christian; Nogai, Axel; Goerner, Martin; Ko, Yon-Dschun; de Wit, Maike; Salwender, Hans; Scheid, Christof; Graeven, Ullrich; Peceny, Rudolf; Staib, Peter; Dieing, Annette; Einsele, Hermann; Jauch, Anna; Hundemer, Michael; Zago, Manola; Pozek, Ema; Benner, Axel; Bokemeyer, Carsten; Goldschmidt, Hartmut; Weisel, Katja C.

Tübinger Autor(en):

Besemer, Britta
Zago, Manola

Published in:

Journal of Clinical Oncology (2024), Bd. 42, H. 1, S. 26-37

Verlagsangabe:

Philadelphia : Lippincott Williams & Wilkins

Language:

English

Full text:

http://dx.doi.org/10.1200/JCO.23.01696

ISSN:

0732-183X